Abstract
A systematic analysis of patient data combined with molecular dynamics simulations and in vitro drug screens have revealed structure–function relationships that, in retrospective analyses, correctly identified drug sensitivity in patients with non–small cell lung cancer harboring atypical oncogenic EGFR mutations.
©2021 American Association for Cancer Research.
2021
American Association for Cancer Research.
You do not currently have access to this content.